HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Jul 27

PMID 35884971

Authors

Iva Klobucar

Vesna Degoricija

Ines Potocnjak

Matias Trbusic

Gudrun Pregartner

Andrea Berghold

Eva Fritz-Petrin

Hansjorg Habisch

Tobias Madl

Sasa Frank

Affiliations

Soon will be listed here.

Abstract

The prognostic value of the subset of high-density lipoprotein (HDL) particles containing apolipoprotein (apo)A-II (HDL-apoA-II) in acute heart failure (AHF) remains unexplored. In this study, baseline serum levels of HDL-apoA-II (total and subfractions 1−4) were measured in 315 AHF patients using NMR spectroscopy. The mean patient age was 74.2 ± 10.5 years, 136 (43.2%) were female, 288 (91.4%) had a history of cardiomyopathy, 298 (94.6%) presented as New York Heart Association class 4, and 118 (37.5%) patients died within 1 year after hospitalization for AHF. Multivariable Cox regression analyses, adjusted for age and sex as well as other clinical and laboratory parameters associated with 1-year mortality in the univariable analyses, revealed a significant inverse association of HDL-apoA-II (hazard ratio (HR) 0.67 per 1 standard deviation (1 SD) increase, 95% confidence interval (CI) 0.47−0.94, p = 0.020), HDL2-apoA-II (HR 0.72 per 1 SD increase, 95% CI 0.54−0.95, p = 0.019), and HDL3-apoA-II (HR 0.59 per 1 SD increase, 95% CI 0.43−0.80, p < 0.001) with 1-year mortality. We conclude that low baseline HDL-apoA-II, HDL2-apoA-II, and HDL3-apoA-II serum levels are associated with increased 1-year mortality in AHF patients and may thus be of prognostic value in AHF.

Citing Articles

Association of Small HDL Subclasses with Mortality Risk in Chronic Kidney Disease.

Stadler J, Borenich A, Pammer A, Emrich I, Habisch H, Madl T Antioxidants (Basel). 2025; 13(12.

PMID: 39765838 PMC: 11673888. DOI: 10.3390/antiox13121511.

High-Density Lipoprotein and Heart Failure.

Xing L, Liu Y, Wang J, Tian P, Liu P Rev Cardiovasc Med. 2024; 24(11):321.

PMID: 39076447 PMC: 11272862. DOI: 10.31083/j.rcm2411321.

Advanced Oxidation Protein Products Are Strongly Associated with the Serum Levels and Lipid Contents of Lipoprotein Subclasses in Healthy Volunteers and Patients with Metabolic Syndrome.

Klobucar I, Hofmann L, Habisch H, Lechleitner M, Klobucar L, Trbusic M Antioxidants (Basel). 2024; 13(3).

PMID: 38539872 PMC: 10968302. DOI: 10.3390/antiox13030339.

Low Valine Serum Levels Predict Increased 1-Year Mortality in Acute Heart Failure Patients.

Klobucar I, Vidovic L, Arih I, Lechleitner M, Pregartner G, Berghold A Biomolecules. 2023; 13(9.

PMID: 37759723 PMC: 10527293. DOI: 10.3390/biom13091323.

APOA2: New Target for Molecular Hydrogen Therapy in Sepsis-Related Lung Injury Based on Proteomic and Genomic Analysis.

Wang Y, Fan Y, Jiang Y, Wang E, Song Y, Chen H Int J Mol Sci. 2023; 24(14).

PMID: 37511084 PMC: 10379236. DOI: 10.3390/ijms241411325.

References

Castellani L, Navab M, Van Lenten B, Hedrick C, Hama S, Goto A . Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest. 1997; 100(2):464-74. PMC: 508211. DOI: 10.1172/JCI119554. View

James R, Hochstrasser D, Tissot J, Funk M, Appel R, Barja F . Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res. 1988; 29(12):1557-71. View

Mishra M, De Geest B . High-Density Lipoprotein-Targeted Therapies for Heart Failure. Biomedicines. 2020; 8(12). PMC: 7767106. DOI: 10.3390/biomedicines8120620. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Weng W, Brandenburg N, Zhong S, Halkias J, Wu L, Jiang X . ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice. J Lipid Res. 1999; 40(6):1064-70. View

Iwaoka M, Obata J, Abe M, Nakamura T, Kitta Y, Kodama Y . Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail. 2007; 13(4):247-53. DOI: 10.1016/j.cardfail.2007.01.007. View

Teis A, Cediel G, Amigo N, Julve J, Aranyo J, Andres-Cordon J . Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure. Sci Rep. 2021; 11(1):3141. PMC: 7862293. DOI: 10.1038/s41598-021-82861-6. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Spillmann F, De Geest B, Muthuramu I, Amin R, Miteva K, Pieske B . Apolipoprotein A-I gene transfer exerts immunomodulatory effects and reduces vascular inflammation and fibrosis in ob/ob mice. J Inflamm (Lond). 2016; 13:25. PMC: 4969975. DOI: 10.1186/s12950-016-0131-6. View

10.

Ambrosy A, Pang P, Khan S, Konstam M, Fonarow G, Traver B . Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013; 34(11):835-43. DOI: 10.1093/eurheartj/ehs444. View

11.

Kido T, Kurata H, Kondo K, Itakura H, Okazaki M, Urata T . Bioinformatic Analysis of Plasma Apolipoproteins A-I and A-II Revealed Unique Features of A-I/A-II HDL Particles in Human Plasma. Sci Rep. 2016; 6:31532. PMC: 4985746. DOI: 10.1038/srep31532. View

12.

Ibrahim N, Januzzi Jr J . Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018; 123(5):614-629. DOI: 10.1161/CIRCRESAHA.118.312706. View

13.

Mitchell C, Rahko P, Blauwet L, Canaday B, Finstuen J, Foster M . Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2018; 32(1):1-64. DOI: 10.1016/j.echo.2018.06.004. View

14.

Mishra M, Muthuramu I, Kempen H, De Geest B . Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. Sci Rep. 2020; 10(1):8382. PMC: 7239951. DOI: 10.1038/s41598-020-65255-y. View

15.

Potocnjak I, Degoricija V, Trbusic M, Pregartner G, Berghold A, Marsche G . Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Sci Rep. 2017; 7:46642. PMC: 5394530. DOI: 10.1038/srep46642. View

16.

Maiga S, Kalopissis A, Chabert M . Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie. 2013; 96:56-66. DOI: 10.1016/j.biochi.2013.08.027. View

17.

Schultz J, Verstuyft J, Gong E, NICHOLS A, Rubin E . Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993; 365(6448):762-4. DOI: 10.1038/365762a0. View

18.

Warnick G, Knopp R, Fitzpatrick V, Branson L . Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990; 36(1):15-9. View

19.

Ambrosy A, Fonarow G, Butler J, Chioncel O, Greene S, Vaduganathan M . The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014; 63(12):1123-1133. DOI: 10.1016/j.jacc.2013.11.053. View

20.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016; 69(12):1167. DOI: 10.1016/j.rec.2016.11.005. View